CoMind develops non-invasive brain monitoring systems and clinical analytics platforms for use in acute care settings. Founded in 2018 and based in London, the company specialises in neurophotonics and neurotechnology, combining photonics hardware with advanced AI algorithms to deliver real-time neurophysiological measurements at the bedside.
The company's flagship product, CoMind One, measures cerebral perfusion, autoregulation, and intracranial pressure without invasive procedures. This approach eliminates the need for insertion of monitoring devices, reducing patient risk whilst providing clinicians with immediate insight into neurophysiological status. The system is designed for deployment in intensive care units, surgical theatres, and emergency departments.
CoVision, the company's AI-powered analytics platform, translates raw monitoring data into predictive clinical insights intended to improve patient safety and outcomes whilst reducing healthcare costs. The platform extends across the care continuum, from initial diagnosis through treatment and recovery. Together, these products address a clinical need for non-invasive alternatives to existing monitoring methods in neurocritical care.
